indacaterol maleate / mometasone furoate
Sponsors
Novartis
Conditions
Asthma
Phase 2
Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma
CompletedNCT00557440
Start: 2007-11-30End: 2008-04-30Updated: 2013-03-21
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma
CompletedNCT00605306
Start: 2008-01-31End: 2008-04-30Updated: 2013-04-22